Oxaprozine [Inn-French] en es it fr


Oxaprozine [Inn-French] Nombres de marca, Oxaprozine [Inn-French] Analogos

Oxaprozine [Inn-French] Marca los nombres de mezcla

  • No information avaliable
  • Oxaprozine [Inn-French] Formula quimica


    Oxaprozine [Inn-French] RX enlace


    Oxaprozine [Inn-French] FDA hoja

    Oxaprozine_[Inn-French] FDA

    Oxaprozine [Inn-French] MSDS (hoja de seguridad de materiales)

    Oxaprozine_[Inn-French] MSDS

    Oxaprozine [Inn-French] Sintesis de referencia

    No hay información disponible

    Oxaprozine [Inn-French] Peso molecular

    293.317 g/mol

    Oxaprozine [Inn-French] Punto de fusion

    158 - 159 oC

    Oxaprozine [Inn-French] H2O Solubilidad


    Oxaprozine [Inn-French] Estado


    Oxaprozine [Inn-French] LogP


    Oxaprozine [Inn-French] Formas de dosificacion


    Oxaprozine [Inn-French] Indicacion

    Se utiliza para aliviar la inflamación, hinchazón, rigidez y dolor en las articulaciones asociados con la artritis reumatoide y la osteoartritis.

    Oxaprozine [Inn-French] Farmacologia

    Oxaprozina es un fármaco antiinflamatorio no esteroideo (AINE) con propiedades analgésicas y antipiréticas. Oxaprozina se utiliza para tratar la artritis reumatoide, osteoartritis, dismenorrea, y para aliviar el dolor moderado.

    Oxaprozine [Inn-French] Absorcion

    Oxaprozina es del 95% absorbe por vía oral. Los alimentos pueden reducir la tasa de absorción de oxaprozina, pero el grado de absorción no se modifica. Los antiácidos no afectan significativamente el alcance y la velocidad de absorción de oxaprozina.

    Oxaprozine [Inn-French] Toxicidad

    Ratón por vía oral, LD50 = 1210 mg / kg, conejo Oral: LD50 = 172 mg / kg; Oral, rata: DL50 = 4470 mg / kg

    Oxaprozine [Inn-French] Informacion de Pacientes

    Daypro, like other drugs of its class, can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in hospitalization and even fatal outcomes. Although serious gastrointestinal tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up.

    Patients should report to their physicians the signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, weight gain, or edema.

    Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and “flu-like” symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.

    Patients should also be instructed to seek immediate emergency help in the case of an anaphylactoid reaction.

    In late pregnancy, as with other NSAIDs, Daypro should be avoided because it will cause premature closure of the ductus arteriosus.

    Oxaprozine [Inn-French] Organismos afectados

    Humanos y otros mamíferos